Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419272 · ClinicalTrials.gov registry record · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
A Phase 4 study of Epilepsy, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 226
- Enrollment target
- 4
- Study locations
NCT04419272: Recruiting Phase 4 study of Epilepsy, sponsored by VA Office of Research and Development.
NCT04419272 is a Phase 4 study of Epilepsy that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 226 participants, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04419272, a Phase 4 study of Epilepsy, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 226 participants
- Enrollment target
- 4
- Study locations
Study Summary
Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinking problems due to epilepsy. In this study, participants will be assigned randomly (i.e., by flip of a coin), to a group that takes MPH and a group that takes a placebo (sugar pill). Participants will not know the group to which they have been assigned. Tests of attention and memory will be completed before taking the study pills and at Week 8. All participants will then have the option of taking MPH for the next two months, and attention and memory will be tested again at Week 16. The study will determine whether methylphenidate is helpful for the treatment of attention and memory problems in adults with epilepsy, and whether the medication is safe and beneficial when taken over an extended time period.
Primary Outcome
Conners Continuous Performance Test (CPT) d' value, a measure of attention, compared post-placebo vs. post-methylphenidate (MPH) in a double-blind, parallel group, placebo controlled, randomized design
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Methylphenidate
Study Locations (4)
Florida
- Miami VA Healthcare System, Miami, FL - Miami
Massachusetts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston
New York
- VA NY Harbor Healthcare System, New York, NY - New York
Oregon
- VA Portland Health Care System, Portland, OR - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 4 |
What NCT04419272 shows while recruiting
NCT04419272 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04419272 reports a single indexed study location in Florida, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04419272 about?
NCT04419272 is a clinical study titled "Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits". Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinking problems due to epilepsy. In this study, participants will be assigned randomly (i.e., by flip of...
What is the current status of trial NCT04419272?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 226 participants. The study started on 2023-08-14. Estimated completion is 2027-09-30.
What conditions does trial NCT04419272 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT04419272?
The interventions under investigation include: Placebo (OTHER), Methylphenidate (DRUG).
Who is sponsoring clinical trial NCT04419272?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04419272 being conducted?
This trial has 4 study locations across Florida, Massachusetts, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04419272's enrollment target sits among peer trials
226 27th of 160 higher than 134 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care
RECRUITING · Phase 4
-
Epidiolex® for Anxiety in Pediatric Epilepsy
COMPLETED · Phase 4
-
Levetiracetam: The Anti-Convulsant of Choice for Elderly Patients With Dementia
COMPLETED · Phase 4
-
Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy
COMPLETED · Phase 4
-
Levetiracetam for Benign Rolandic Epilepsy
COMPLETED · Phase 4
-
Fycompa Titration Intervals and Effects on Retention Rate
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
- NCT06106945 · 226 participants · Phase 1
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI